Literature DB >> 21859731

Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo.

Igor Theurl1, Andrea Schroll, Manfred Nairz, Markus Seifert, Milan Theurl, Thomas Sonnweber, Hasan Kulaksiz, Guenter Weiss.   

Abstract

BACKGROUND: Increased levels of hepcidin, the master regulator of iron homeostasis, contribute to the diversion of iron underlying the anemia of chronic disease. Yet hepcidin levels are low in anemia of chronic disease with concomitant true iron deficiency. Here we clarify the different underlying pathways regulating hepcidin expression under these conditions in vivo. DESIGN AND METHODS: We used rat models of iron deficiency anemia, anemia of chronic disease and anemia of chronic disease with concomitant true iron deficiency and investigated upstream signaling pathways controlling hepcidin transcription in the liver. Protein and mRNA levels of iron metabolism genes and genes involved in SMAD1/5/8 and STAT3 signaling were determined by RT-PCR, Western blotting and immunohistochemistry.
RESULTS: SMAD1/5/8 phosphorylation and in parallel hepcidin mRNA expression were increased in anemia of chronic disease but significantly down-regulated in anemia of chronic disease with concomitant iron deficiency, either on the basis of phlebotomy or dietary iron restriction. Iron deficiency resulted in reduced bone morphogenetic protein-6 expression and impaired SMAD1/5/8 phosphorylation and trafficking, two key events for hepcidin transcription. Reduced SMAD1/5/8 activity in association with phlebotomy was paralleled by increased expression of the inhibitory factor, SMAD7, dietary iron restriction appeared to impair hepcidin transactivating SMAD pathways via reduction of membrane bound hemojuvelin expression.
CONCLUSIONS: This study evaluated hepcidin signaling pathways in anemia of chronic disease with/without concomitant iron deficiency in vivo. While iron deficiency in general decreased bone morphogenetic protein-6 expression, phlebotomy or dietary iron restriction inhibited inflammation driven SMAD1/5/8 mediated hepcidin formation by different pathways, indicating alternate hierarchic signaling networks as a function of the mode and kinetics of iron deficiency. Nonetheless, iron deficiency inducible regulatory pathways can reverse inflammation mediated stimulation of hepcidin expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859731      PMCID: PMC3232257          DOI: 10.3324/haematol.2011.048926

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  56 in total

Review 1.  Transcriptional regulation of erythropoiesis: an affair involving multiple partners.

Authors:  Alan B Cantor; Stuart H Orkin
Journal:  Oncogene       Date:  2002-05-13       Impact factor: 9.867

2.  Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.

Authors:  Igor Theurl; Elmar Aigner; Milan Theurl; Manfred Nairz; Markus Seifert; Andrea Schroll; Thomas Sonnweber; Lukas Eberwein; Derrick R Witcher; Anthony T Murphy; Victor J Wroblewski; Eva Wurz; Christian Datz; Guenter Weiss
Journal:  Blood       Date:  2009-03-17       Impact factor: 22.113

3.  BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression.

Authors:  Léon Kautz; Delphine Meynard; Céline Besson-Fournier; Valérie Darnaud; Talal Al Saati; Hélène Coppin; Marie-Paule Roth
Journal:  Blood       Date:  2009-07-21       Impact factor: 22.113

4.  Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes.

Authors:  Guillemette Ramey; Jean-Christophe Deschemin; Sophie Vaulont
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

5.  Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD.

Authors:  Guillem Casanovas; Katarzyna Mleczko-Sanecka; Sandro Altamura; Matthias W Hentze; Martina U Muckenthaler
Journal:  J Mol Med (Berl)       Date:  2009-02-20       Impact factor: 4.599

6.  Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli.

Authors:  Hua Huang; Marco Constante; Antonio Layoun; Manuela M Santos
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

7.  ER stress controls iron metabolism through induction of hepcidin.

Authors:  Chiara Vecchi; Giuliana Montosi; Kezhong Zhang; Igor Lamberti; Stephen A Duncan; Randal J Kaufman; Antonello Pietrangelo
Journal:  Science       Date:  2009-08-14       Impact factor: 47.728

8.  Lack of the bone morphogenetic protein BMP6 induces massive iron overload.

Authors:  Delphine Meynard; Léon Kautz; Valérie Darnaud; François Canonne-Hergaux; Hélène Coppin; Marie-Paule Roth
Journal:  Nat Genet       Date:  2009-03-01       Impact factor: 38.330

9.  Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance.

Authors:  Jodie L Babitt; Franklin W Huang; Yin Xia; Yisrael Sidis; Nancy C Andrews; Herbert Y Lin
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.

Authors:  Laura Silvestri; Alessia Pagani; Antonella Nai; Ivana De Domenico; Jerry Kaplan; Clara Camaschella
Journal:  Cell Metab       Date:  2008-10-30       Impact factor: 27.287

View more
  32 in total

Review 1.  Anemia of inflammation.

Authors:  Guenter Weiss; Tomas Ganz; Lawrence T Goodnough
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 2.  The liver: conductor of systemic iron balance.

Authors:  Delphine Meynard; Jodie L Babitt; Herbert Y Lin
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

3.  Does iron let boys grow faster?!

Authors:  Günter Weiss
Journal:  Haematologica       Date:  2019-08       Impact factor: 9.941

4.  Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia.

Authors:  Gianluca Abbati; Federica Incerti; Chiara Boarini; Francesca Pileri; Davide Bocchi; Paolo Ventura; Elena Buzzetti; Antonello Pietrangelo
Journal:  Intern Emerg Med       Date:  2018-11-29       Impact factor: 3.397

5.  Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.

Authors:  Matthew Sheetz; Philip Barrington; Sophie Callies; Paul H Berg; Juliet McColm; Thomas Marbury; Brian Decker; Gregory L Dyas; Stephanie M E Truhlar; Robert Benschop; Donmienne Leung; Jolene Berg; Derrick R Witcher
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

6.  The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6.

Authors:  Claire Mayeur; Lisa K Lohmeyer; Patricio Leyton; Sonya M Kao; Alexandra E Pappas; Starsha A Kolodziej; Ester Spagnolli; Binglan Yu; Rita L Galdos; Paul B Yu; Randall T Peterson; Donald B Bloch; Kenneth D Bloch; Andrea U Steinbicker
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

7.  Chronic inflammation and iron metabolism.

Authors:  Erin A Osterholm; Michael K Georgieff
Journal:  J Pediatr       Date:  2015-02-13       Impact factor: 4.406

8.  Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

Authors:  Malte Asshoff; Verena Petzer; Matthew R Warr; David Haschka; Piotr Tymoszuk; Egon Demetz; Markus Seifert; Wilfried Posch; Manfred Nairz; Pat Maciejewski; Peter Fowles; Christopher J Burns; Gregg Smith; Kay-Uwe Wagner; Guenter Weiss; J Andrew Whitney; Igor Theurl
Journal:  Blood       Date:  2017-02-10       Impact factor: 22.113

Review 9.  The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.

Authors:  Kimberly Zumbrennen-Bullough; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

10.  A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.

Authors:  Chia Chi Sun; Valentina Vaja; Shanzhuo Chen; Igor Theurl; Aaron Stepanek; Diane E Brown; Maria D Cappellini; Guenter Weiss; Charles C Hong; Herbert Y Lin; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-01-22       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.